This further questions the clinical usefulness of this device, at least with the software version used in this study.ConclusionsThe results of the present study show that changes in systemic arterial resistance alter the reliability of the FTV-system; even if using the modified second-generation software (version 1.14). This may help to explain the variable results of studies comparing Vandetanib molecular weight the FTV-system with other CO monitoring techniques, questions the usefulness of this device for hemodynamic monitoring of patients undergoing rapid changes in arterial blood pressure, and should be kept in mind when using vasopressors during FTV-guided hemodynamic optimization. Further studies are needed to reveal if the most recent modification of the FTV-system software (the third generation) improves the reliability of this technology.
Key messages? Variations in arterial blood pressure lead to parallel changes in CO measurements by the second generation of the FTV system.? This questions the usefulness of this device for hemodynamic monitoring of patients undergoing rapid changes in arterial blood pressure and should be kept in mind when using vasopressors during Flowtrac/Vigileo? – guided hemodynamic optimization.AbbreviationsCABG: coronary artery bypass grafting; CI: confidence interval; CO: cardiac output; FTV: FlowTrac-Vigileo?; GP: graft preparation; ICU: intensive care unit; IPATD: intermittent pulmonary arterial thermodilution; MAP: mean arterial blood pressure.Competing interestsThe authors SE, ZG, VD, IB, JS, HH, and KUB declare that they have no competing interests.
MH received scientific support and/or honoraria for lectures from Edwards Lifesciences, Irvine, CA, USA, the manufacturer of the FloTrac/Vigileo? – system, Osypka Medical, Germany, and Covidien, Germany.Authors’ contributionsSE, JS, and MH designed the study, performed the statistical analyses and drafted the manuscript. SE, ZG, VD, and IB coordinated the study, were responsible for patient recruitment and data acquisition. HH and KUB were involved in the interpretation of the data and manuscript drafting. All authors read and approved the final manuscript.NotesSee related commentary by Camporota and Beale, http://ccforum.com/content/14/2/124AcknowledgementsWe deeply acknowledge the continuous support of our institutional statistician Michael H��ppe, PhD.
In the papers we appraised, patients with a tracheostomy tube in situ discharged from an ICU to a general ward who received care from a dedicated Dacomitinib multidisciplinary team as compared with standard care showed reductions in time to decannulation, length of stay and adverse events. Impacts on quality of care were not reported.These results should be interpreted with caution due to the methodological weaknesses in the historical control studies.IntroductionAppropriate care for patients with tracheostomies in hospital settings is an important issue.